Your browser doesn't support javascript.
loading
[EFFECTIVE TREATMENT FOR BULLOUS PEMPHIGOID WITH OMALIZUMAB].
Neumark, Michal; Tal, Yuval; Zlotogorski, Abraham; Molho-Pessach, Vered.
Afiliação
  • Neumark M; Department of Dermatology, Division of Internal Medicine, Hadassah Medical Center, Hebrew University, Faculty of Medicine, Jerusalem, Israel.
  • Tal Y; Clinical Immunology Unit, Division of Internal Medicine, Hadassah Medical Center, Hebrew University, Faculty of Medicine, Jerusalem, Israel.
  • Zlotogorski A; Department of Dermatology, Division of Internal Medicine, Hadassah Medical Center, Hebrew University, Faculty of Medicine, Jerusalem, Israel.
  • Molho-Pessach V; Department of Dermatology, Division of Internal Medicine, Hadassah Medical Center, Hebrew University, Faculty of Medicine, Jerusalem, Israel.
Harefuah ; 159(1): 29-30, 2020 Jan.
Article em He | MEDLINE | ID: mdl-31930804
INTRODUCTION: Bullous pemphigoid is a common autoimmune blistering disorder, characterized by sub-epidermal bullae formation, that tends to affect older patients. We report on a 78 -year-old male patient suffering from bullous pemphigoid, whose disease persisted despite treatment with potent topical corticosteroids, systemic tetracyclines, prednisone and azathioprine. Recently, omalizumab was reported to be effective in several patients with resistant bullous pemphigoid. Omalizumab is a monoclonal antibody against IgE, approved for the treatment of asthma and chronic urticaria and known for its excellent safety profile. The patient was treated accordingly with omalizumab for his bullous pemphigoid with dramatic and rapid regression of his disease.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Penfigoide Bolhoso / Antialérgicos / Omalizumab Limite: Aged / Humans / Male Idioma: He Revista: Harefuah Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Israel País de publicação: Israel
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Penfigoide Bolhoso / Antialérgicos / Omalizumab Limite: Aged / Humans / Male Idioma: He Revista: Harefuah Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Israel País de publicação: Israel